Saturday 17 October 2026
Export BCRX’s income statement to Excel — free account
BioCryst Pharmaceuticals, Inc.
BCRX Healthcare Drug Manufacturers Specialty & Generic
BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024. In the quarter to June 2026, revenue grew 33.6%, EPS grew 1,450.0%, free cash flow grew 153.2% and total debt rose 15.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
7.79
0.23
−2.87%
Follow BCRX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 87.84% | 91.07% | (88.68%) | 2.05% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
5 | 4 | 7 | 5 | |
| (75.79%) | (96.92%) | 52.53% | (1.87%) | ||
ROIC |
(610.55%) | (356.26%) | 245.61% | 66.46% | |
Return on Tangible Assets |
(135.02%) | (244.12%) | 121.56% | (5.05%) | |
Average Days of Receivables |
42.98 | 45.03 | 44.57 | 55.57 | |
Free Cash Flow per Share |
1.47 | 1.28 | 1.65 | 0.23 | |
Free Cash Flow |
373.93 | 310.92 | 345.45 | 47.86 | |
Capital Expenditures |
(2.21) | (2.18) | (1.92) | (2.34) | |
| Other line items | |||||
Cash ROIC |
50.66% | 57.00% | 54.26% | 9.60% | |
Accounts Receivable Turnover |
9.32 | 8.74 | 9.41 | 7.32 | |
Accounts Payable Turnover |
2.09 | 1.89 | 1.39 | 1.64 | |
Inventory Turnover |
3.77 | 3.09 | 2.83 | 2.45 | |
Average Days of Payables |
199.87 | 201.15 | 302.83 | 129.86 | |
Days of Inventory on Hand |
105.63 | 109.86 | 103.29 | 122.05 | |
Tax Rate |
0.01 | 0.01 | (0.01) | 0.33 | |
Research and Development Expense of Revenue |
21.02% | 21.36% | 18.99% | 29.13% | |
Selling, General and Administrative Expense of Revenue |
35.86% | 40.73% | 39.85% | 55.58% | |
Share Based Compensation of Revenue |
7.77% | 9.00% | 9.72% | 13.77% | |
Interest Coverage |
(4.16) | (5.08) | 4.32 | 0.85 | |
Operating CF/Net income |
(0.98) | (0.68) | 1.32 | (5.72) | |
Depreciation/Fixed assets |
(0.03) | (0.10) | (0.33) | (0.56) | |
Capex/Depreciation |
7.08 | 2.24 | 0.65 | 0.50 | |
Revenue per Share |
3.70 | 3.66 | 4.17 | 2.85 | |
Operating CF per Share |
1.48 | 1.29 | 1.66 | 0.24 | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates